Continuous strong underlying growth with good profitability and cash flow

· Growth in local currency was 15 percent. Sales amounted to SEK 75 (72) million, corresponding to an increase of 5 percent in SEK.

· Operating income before research and development costs increased by 21 percent and amounted to SEK 21 (17) million.

· Operating income (EBIT) increased by 14 percent and amounted to SEK 10 (9) million. The operating margin was 13 (12) percent.

· The Group's net income amounted to SEK 10 (8) million, which gives earnings per share of SEK 0.50 (0.43)

· The cash flow from operating activities was SEK 7 (-3).

· The clinical study on STEEN Solution™ was completed during the period.

· A collaboration agreement was entered into with Finn-Medi Research Ltd concerning the Stem Cells area.

April 27, 2010
Gothenburg

Magnus Nilsson
CEO

Queries should be addressed to:
Magnus Nilsson, CEO; phone +46 31 721 80 61
Eva Nilsagård, CFO, phone +46 31 721 80 13